RTI Biologics (Nasdaq: RTIX ) is expected to report Q4 earnings around Jan. 31. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict RTI Biologics's revenues will increase 5.1% and EPS will drop 0.0%.
The average estimate for revenue is $45.1 million. On the bottom line, the average EPS estimate is $0.04.
Last quarter, RTI Biologics booked revenue of $44.6 million. GAAP reported sales were 5.5% higher than the prior-year quarter's $42.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.05. GAAP EPS of $0.05 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 48.7%, 300 basis points better than the prior-year quarter. Operating margin was 9.2%, 170 basis points better than the prior-year quarter. Net margin was 6.3%, 20 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $178.6 million. The average EPS estimate is $0.18.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 212 members out of 222 rating the stock outperform, and 10 members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 50 give RTI Biologics a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on RTI Biologics is outperform, with an average price target of $4.62.
Is RTI Biologics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.